A study to confirm persistence/recrudescence of trachoma and understand factors facilitating on-going transmission in six districts across Oromia and SNNP regions of Ethiopia

Is there concordance in the TF, infection and serology data (at EU level) in confirming persistence and/or recrudescence of trachoma and the need for on-going interventions?

(1)    How does TF, anti-Ct antibody and infection data correlate at cluster level and what implications does this have for targeting programmatic interventions? 

(2)    Are there treatment coverage, geographic, demographic, and WASH factors that are correlated with higher pgp3 antibody, Ct infection and/or TF prevalence that could inform more effective program interventions? 

(3)    Are there sociocultural and behavioural factors that are associated with higher TF prevalence that could inform more effective program interventions?